Objective:

To investigate the effects of Bifidobacterium-mediated HSV-TK/GCV therapy on protein phosphorylation and its implications for tumor treatment.

Approach:

Key Findings:

• BF-TK/GCV treatment resulted in 337 differentially abundant phosphopeptides (DAPs), with 108 DAPs significantly altered compared to the BF/GCV group.
• GO analysis revealed enrichment in protein kinase activity, cell cycle regulation, and DNA replication.
• BF-TK/GCV differentially regulated the phosphorylation status of HIF-1α, mTOR, PKM2, and PD-L1 in a site-specific manner.
• BF-TK/GCV suppressed tumor growth and significantly prolonged survival in tumor-bearing mice.

Interpretation:

BF-TK/GCV reprograms the phosphoproteome in a site- and pathway-specific manner.

Limitations:

• The study primarily focuses on specific tumor models and may not be generalizable to all cancer types.
• Further research is needed to fully elucidate the long-term effects and mechanisms of BF-TK/GCV treatment.

Conclusion:

BF-TK/GCV therapy provides insights into cancer treatment strategies through targeted modulation of protein phosphorylation.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.